
Avanos Medical (AVNS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
167.5M
Gross Profit
89.8M
53.61%
Operating Income
10.3M
6.15%
Net Income
6.6M
3.94%
EPS (Diluted)
$0.14
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
268.4M
Shareholders Equity
839.4M
Debt to Equity
0.32
Cash Flow Metrics
Operating Cash Flow
39.9M
Free Cash Flow
19.0M
Revenue & Profitability Trend
Avanos Medical Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 687.8M | 673.3M | 684.1M | 587.0M | 714.8M |
Cost of Goods Sold | 306.5M | 293.6M | 289.9M | 287.8M | 341.5M |
Gross Profit | 381.3M | 379.7M | 394.2M | 299.2M | 373.3M |
Gross Margin % | 55.4% | 56.4% | 57.6% | 51.0% | 52.2% |
Operating Expenses | |||||
Research & Development | 26.2M | 27.2M | 29.2M | 30.6M | 34.9M |
Selling, General & Administrative | 318.5M | 335.0M | 326.5M | 285.3M | 332.6M |
Other Operating Expenses | -3.9M | 13.3M | 3.0M | 22.3M | 51.9M |
Total Operating Expenses | 340.8M | 375.5M | 358.7M | 338.2M | 419.4M |
Operating Income | 40.5M | 4.2M | 35.5M | -39.0M | -46.1M |
Operating Margin % | 5.9% | 0.6% | 5.2% | -6.6% | -6.4% |
Non-Operating Items | |||||
Interest Income | 5.1M | 2.9M | 1.2M | 200.0K | 1.2M |
Interest Expense | 12.2M | 15.0M | 10.0M | 3.3M | 15.6M |
Other Non-Operating Income | -436.7M | - | - | - | - |
Pre-tax Income | -403.3M | -7.9M | 26.7M | -42.1M | -60.5M |
Income Tax | -17.0M | 2.0M | 5.2M | -11.2M | -33.3M |
Effective Tax Rate % | 0.0% | 0.0% | 19.5% | 0.0% | 0.0% |
Net Income | -392.1M | -61.8M | 50.5M | 6.3M | -27.2M |
Net Margin % | -57.0% | -9.2% | 7.4% | 1.1% | -3.8% |
Key Metrics | |||||
EBITDA | 91.1M | 53.2M | 84.4M | -500.0K | -2.0M |
EPS (Basic) | $-8.53 | $-1.32 | $1.08 | $0.11 | $-0.57 |
EPS (Diluted) | $-8.53 | $-1.32 | $1.07 | $0.11 | $-0.57 |
Basic Shares Outstanding | 46000000 | 46600000 | 46900000 | 48100000 | 47800000 |
Diluted Shares Outstanding | 46000000 | 46600000 | 46900000 | 48100000 | 47800000 |
Income Statement Trend
Avanos Medical Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 107.7M | 87.7M | 127.7M | 118.5M | 111.5M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 127.9M | 128.7M | 155.7M | 118.2M | 108.6M |
Inventory | 138.8M | 163.2M | 132.3M | 159.3M | 168.9M |
Other Current Assets | 14.1M | 28.8M | 13.9M | 18.6M | 18.9M |
Total Current Assets | 393.4M | 487.0M | 624.1M | 427.6M | 467.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 34.1M | 26.8M | 27.5M | 38.6M | 48.3M |
Goodwill | 1.0B | 1.8B | 1.8B | 1.7B | 1.8B |
Intangible Assets | 112.3M | 239.5M | 234.2M | 141.2M | 157.7M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 48.1M | 25.8M | 22.2M | 26.5M | 21.8M |
Total Non-Current Assets | 760.8M | 1.2B | 1.2B | 1.2B | 1.2B |
Total Assets | 1.2B | 1.7B | 1.8B | 1.6B | 1.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 54.3M | 56.3M | 67.9M | 56.4M | 67.6M |
Short-term Debt | 20.3M | 21.4M | 18.2M | 14.7M | 15.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | 63.7M | 7.1M | - | - |
Total Current Liabilities | 165.9M | 234.6M | 191.0M | 139.2M | 166.3M |
Non-Current Liabilities | |||||
Long-term Debt | 149.9M | 187.7M | 258.8M | 172.8M | 233.3M |
Deferred Tax Liabilities | 5.5M | 23.8M | 25.4M | 11.9M | 5.7M |
Other Non-Current Liabilities | 200.0K | 4.1M | 15.7M | 4.7M | 4.8M |
Total Non-Current Liabilities | 159.8M | 221.5M | 304.7M | 193.8M | 250.0M |
Total Liabilities | 325.7M | 456.1M | 495.7M | 333.0M | 416.3M |
Equity | |||||
Common Stock | 500.0K | 500.0K | 500.0K | 500.0K | 500.0K |
Retained Earnings | -707.0M | -314.9M | -253.1M | -303.6M | -315.5M |
Treasury Stock | 99.0M | 85.9M | 66.8M | 21.3M | 9.8M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 828.5M | 1.2B | 1.3B | 1.3B | 1.3B |
Key Metrics | |||||
Total Debt | 170.2M | 209.1M | 277.0M | 187.5M | 248.8M |
Working Capital | 227.5M | 252.4M | 433.1M | 288.4M | 300.9M |
Balance Sheet Composition
Avanos Medical Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -392.1M | -61.8M | 50.5M | 6.3M | -27.2M |
Depreciation & Amortization | 45.5M | 46.1M | 47.7M | 38.3M | 42.9M |
Stock-Based Compensation | 13.8M | 15.8M | 15.9M | 13.2M | 12.1M |
Working Capital Changes | 31.5M | 29.3M | -20.2M | -7.0M | 5.1M |
Operating Cash Flow | -301.3M | 29.4M | 93.9M | 47.4M | 46.7M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | -9.7M | 39.4M | -116.1M | 0 | -4.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -9.7M | 39.4M | -116.1M | 0 | -4.0M |
Financing Activities | |||||
Share Repurchases | -12.8M | -19.1M | -45.5M | -11.5M | -900.0K |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 20.0M | 55.0M | 400.0M | 20.0M | 185.0M |
Debt Repayment | -53.6M | -119.7M | -296.6M | -70.0M | -254.8M |
Financing Cash Flow | -50.2M | -95.5M | 55.0M | -111.5M | 106.6M |
Free Cash Flow | 82.9M | 14.6M | 71.6M | 66.3M | -22.7M |
Net Change in Cash | -361.2M | -26.7M | 32.8M | -64.1M | 149.3M |
Cash Flow Trend
Avanos Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
34.37
Forward P/E
7.19
Price to Book
0.66
Price to Sales
0.81
PEG Ratio
7.19
Profitability Ratios
Profit Margin
-55.80%
Operating Margin
6.15%
Return on Equity
-36.78%
Return on Assets
2.26%
Financial Health
Current Ratio
2.57
Debt to Equity
16.79
Beta
1.12
Per Share Data
EPS (TTM)
$-8.27
Book Value per Share
$18.16
Revenue per Share
$14.99
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
avns | 555.4M | 34.37 | 0.66 | -36.78% | -55.80% | 16.79 |
Abbott Laboratories | 219.8B | 15.85 | 4.50 | 27.98% | 32.43% | 27.09 |
Boston Scientific | 157.5B | 63.38 | 7.09 | 8.42% | 13.55% | 52.16 |
UFP Technologies | 1.8B | 28.51 | 4.96 | 19.36% | 11.59% | 55.05 |
QuidelOrtho | 1.8B | -0.80 | 0.59 | -11.38% | -12.97% | 90.01 |
Alphatec Holdings | 1.6B | -9.63 | -18.58 | 1,144.21% | -25.77% | -6.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.